Yaei Togawa

Dr. Yaei Togawa


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2012 in Case Reports in Dermatological Medicine
Verified
Journal Article
Open access
PDF file
SWS. Wakabayashi
S. Wakabayashi
YTYaei Togawa
Yaei Togawa
KYK. Yoneyama
K. Yoneyama
KSK. Suehiro
K. Suehiro
NKN. Kambe
N. Kambe
HMH. Matsue
H. Matsue
We report the first case of 68-year-old Japanese woman with metastatic HER2-positive extramammary Paget’s disease that showed the validity of trastuzumab monotherapy. We administered trastuzumab at a loading dose of 8 mg/kg i.v., followed by a 6 mg/kg maintenance dose every three weeks according to a protocol for HER2-positive metastatic breast cancers and a near-complete response was achieved after the tenth infusion. The patient experienced a moderate headache and flushing during the first infusion, but had no advanced effects during subsequent infusions with ibuprofen and d-chlorpheniramine maleate. Given the dramatic response, the patient has had 17 infusions of trastuzumab with no disease progression. Thus, trastuzumab has few side effects and is well tolerated for elderly patients. It may become a new choice of the adjubant therapy of this disease.

26 April 2017 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YTYaei Togawa
Yaei Togawa

22 December 2017 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SKS. Kawashima
S. Kawashima
YTYaei Togawa
Yaei Togawa
HMHideaki Miyachi
Hideaki Miyachi
HMH. Matsue
H. Matsue

27 September 2020 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
YAYuta Araki
Yuta Araki
KOKen Okamura
Ken Okamura
TSToru Saito
Toru Saito
KMKazuhiko Matsumoto
Kazuhiko Matsumoto
KNKen Natsuga
Ken Natsuga
TSTamio Suzuki
Tamio Suzuki

5 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
BFBahrul Fikri
Bahrul Fikri
YTYumi Tani
Yumi Tani
KNKazue Nagai
Kazue Nagai
MSMasumi Sahara
Masumi Sahara
CMChisako Mitsuishi
Chisako Mitsuishi
NSNaoki Shimojo
Naoki Shimojo
Soluble CD14 (sCD14) is one of the immunomodulatory factors in breast milk (BM). Although it may be involved in the prevention of atopic symptoms and sensitization to both food and inhalant allergens, conflicting evidence exists concerning its protective effects. In this study, we investigated the relationship between sCD14 in colostrum and 1-month BM, and the development of atopic dermatitis (AD) and sensitization to food and aeroallergens at 9 months of age in infants who were exclusively or almost exclusively breastfed up to 4 months of age. BM samples were collected from lactating mothers who participated in a 2 × 2 factorial, randomized, nontreatment controlled trial study set in Tokyo, which looked at the efficacy of emollients and synbiotics in preventing AD and food allergy in children during the first year of life. A total of 258 colostrum samples and 269 1-month BM samples were analyzed. We found that one-month BM sCD14 levels in the AD group were significantly lower than in the non-AD group. Levels of sCD14 in 1-month BM were not related to allergen sensitization in the overall analysis, but egg white sensitization correlated inversely with 1-month BM sCD14 in infants without AD. The results suggest that sCD14 in BM may be involved in atopic manifestations in early infancy.

23 November 2010 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YTYaei Togawa
Yaei Togawa
YNY. Nakamura
Y. Nakamura
NKN. Kamada
N. Kamada
NKNaotomo Kambe
Naotomo Kambe
YTY. Takahashi
Y. Takahashi
HMH. Matsue
H. Matsue